Dr Reddy's July-September net zooms 106 per cent to Rs217 crore
23 Oct 2009
Dr Reddy's Laboratories Ltd today reported a 106 per cent jump in its after-tax profit at Rs217.3 crore for fiscal second quarter (July-September 2009-10).
Consolidated revenues were up 14 per cent at Rs1,836.8 crore ($382 million) in Q2 FY10 as against Rs1,620 crore ($336 million) in Q2 FY09. Operating income stood at Rs260 crore ($53 million) in Q2 FY10 against Rs180 crore ($37 million) in Q2 FY09.
Earnings before interest, tax, depreciation and appropriation (EBITDA) rose 51 per cent to Rs379.7 crore, as per unaudited financial results under International Financial Reporting Standards (IFRS).
Sequentially, as compared to first quarter of the current fiscal, revenues excluding sumatriptan have grown by 11 per cent.
Consolidated revenues for the first half of the current financial year (April-September 2009-10) rose 17 per cent year-on-year to Rs3,660 crore.
EBITDA for the first half of the fiscal rose 70 per cent to Rs820 crore year-on-year.